The company uses breakthrough microbiome research to address the underlying cause of kidney stones. With a focus on prevention, their novel drug therapy derived from a gut bacterium safely removes oxalate from the body, preventing the recurrence of kidney stones and other renal diseases caused by high levels of oxalate. This has the potential to alleviate the debilitating pain and reduce the significant healthcare costs associated with kidney stones, which cause over 1.3 million emergency room visits and more than $10 billion in expenses annually.